The Quantellect read.As of Nov 19, 2026, 5 active firms cover Definitive Healthcare Corp: 0 rate it Buy or better, 3 sit at Neutral, and 2 rate it Sell or worse, a neutral consensus. Targets range widely, $0.70 to $1.50 (about 2.1x), a sign of real disagreement on valuation. The average target of $1.07 sits 21% below the current $1.35. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.05 next quarter toward $0.19 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Neutral
Strong Buy00%
Buy00%
Neutral360%
Sell240%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$1.07
-21.0% downside
Average target across 3 active firms as of Nov 19, 2026 vs $1.35 current
Highest Target$1.50
Average Target$1.07
Lowest Target$0.70
Detailed analyst forecasts for DH
Showing 1–3 of 3 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 0 of 5 active firms rate DH a Buy (3 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
DH EPS & revenue forecast
EPS · NEXT QUARTER
$0.05
Range $0.04 – $0.05 · 5 analysts · -22% YoY
Next period, 5 analysts expect Definitive Healthcare Corp to earn $0.05 a share (range $0.04 – $0.05), versus $0.06 a year earlier. Full-year consensus is $0.22, growing to $0.19 the year after.
REVENUE · NEXT QUARTER
$56.1M
Range $53.7M – $58.2M · 5 analysts · +0% YoY
Revenue is expected to reach $56.1M (range $53.7M – $58.2M), +0.3% year-over-year. Full-year consensus is $221.4M, rising to $220.5M next year.
Top analysts covering Definitive Healthcare Corp
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on DH.
#1
David Hynes
Canaccord Genuity · Rank #492
Neutral
$3.00+122.2% to target
Overall win rate
30%
+ Follow
#2
Ryan MacDonald
Needham · Rank #579
Neutral
No targeton DH
Overall win rate
19%
+ Follow
#3
GS
Glen Santangelo
Barclays
Sell
$1.00-25.9% to target
Coverage
—
+ Follow
#4
Allen Lutz
B of A Securities
Sell
$0.70-48.1% to target
Coverage
—
+ Follow
#5
Craig Hettenbach
Morgan Stanley
Neutral
$1.50+11.1% to target
Coverage
—
+ Follow
DH stock forecast FAQ
What is DH's average 12-month price target?+
The 3 active firms with a live target average $1.07 for Definitive Healthcare Corp over the next 12 months, ranging from a $1.50 high to a $0.70 low, as of Nov 19, 2026.
Is DH stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 5 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 3 rate it Neutral, and 2 rate it Sell or Strong Sell.
What are the highest and lowest price targets for DH?+
The Street-high target is $1.50 (Morgan Stanley), and the Street-low is $0.70 (B of A Securities). The average of all 3 active-firm targets is $1.07.
How many active Wall Street firms cover DH?+
5 active firms have a recognized rating on Definitive Healthcare Corp as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering DH?+
Among analysts who currently cover DH, David Hynes of Canaccord Genuity has the strongest overall Quantellect track record (Rank #492). Their current call is Neutral with a $3.00 target.
What is Definitive Healthcare Corp's projected EPS for next quarter?+
The consensus estimate is $0.05 per share (range $0.04 – $0.05) across 5 analysts. Full-year EPS is projected at $0.22, rising to $0.19 the following year.
How much revenue is Definitive Healthcare Corp expected to report next quarter?+
Consensus revenue is $56.1M (range $53.7M – $58.2M). Full-year revenue is projected at $221.4M, growing to $220.5M next year.
Have analysts been upgrading or downgrading DH lately?+
As of Nov 19, 2026, 0 of 5 active firms rate DH a Buy (3 Neutral, 2 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their DH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.